CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Magnetic Resonance ImagingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug3369 no intervention. observational cohort study Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Assessing the Effects of Coronavirus Disease (COVID-19) on Multiple Organ Systems and Impact on Quality of Life, Functional Capacity and Mental Health

The C-MORE study is prospective observational holistic longitudinal study which will characterise the prevalence multi-organ injury among COVID-19 survivors post hospital discharge and assess its effects of quality of life, exercise tolerance and mental health.

NCT04510025 Coronavirus Infection Multi-Organ Disorder Diagnostic Test: Magnetic Resonance Imaging
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Characterise and compare the prevalence and extent of lung, heart, liver, kidney, brain injury on magnetic resonance imaging (MRI) in patients with moderate to severe COVID-19 disease with matched uninfected controls.

Measure: Prevalence of damage (quantitative measures of injury) on lung, heart, liver, kidneys and brain MRI.

Time: 6 months

Secondary Outcomes

Description: Characterise and compare the prevalence and extent of lung, heart, liver and kidney, brain injury on magnetic resonance imaging (MRI) in patients with moderate to severe COVID-19 disease with matched uninfected controls.

Measure: Prevalence of damage (quantitative measures of injury) on lungs, heart, liver, kidneys and brain on MRI.

Time: 3 and 12 months

Description: Characterise and compare the prevalence of cardiac, renal and liver injury on blood test in COVID-19 survivors and controls.

Measure: Prevalence of acute/chronic cardiac, renal and liver injury on blood tests.

Time: 3, 6,12 months

Description: Characterise and compare VO2 max on cardiopulmonary exercise testing in COVID-19 survivors and controls.

Measure: VO2 max on cardiopulmonary exercise testing

Time: 3, 6,12 months

Description: Characterise and compare the prevalence of lung function test abnormalities among survivors and controls.

Measure: Prevalence of abnormal lung function test (any of the following: Forced expiratory volume in 1 second (FEV1)< 80% of predicted FEV1, or forced vital capacity (FVC)<80% predicted, ratio of FEV1/FVC >0.7 or diffusion lung capacity (<80% predicted))

Time: 3, 6,12 months

Description: For each of the eight domains that the SF36 measures an aggregate percentage score is produced. The percentage scores range from 0% (lowest or worst possible level of functioning) to 100% (highest or best possible level of functioning).

Measure: Quality of life - Short form-36 SF-36 score

Time: 3, 6,12 months

Description: Described and compare the prevalence of impaired cognition (MoCA) between COVID-19 survivors and controls. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.

Measure: Prevalence of impaired cognitive function on Montreal Cognitive assessment (MoCA<26)

Time: 3, 6,12 months

Description: Compare 6-minute walk distance between COVID-19 survivors and controls.

Measure: 6-minute walk distance

Time: 3, 6,12 months

Description: Compare prevalence and severity of anxiety between COVID-19 survivors and controls.

Measure: Severity of anxiety on GAD-7 (Score)

Time: 3, 6,12 months

Description: Compare prevalence and severity of depression among COVID-19 survivors and controls. PHQ-9 total score for the nine items ranges from 0 to 27. Scores of 5, 10, 15, and 20 represent outpoints for mild, moderate, moderately severe and severe depression, respectively.

Measure: Severity of depression on PHQ-9 (Score)

Time: 3, 6,12 months

Description: To assess the association of multi organ damage on MRI and inflammatory response.

Measure: Association between the extent of multi-organ injury (continuous variable) and markers of inflammation (white cell count).

Time: 3,6,12 months

Description: To assess the association of ongoing symptomatology and multi-organ injury/inflammation.

Measure: Correlation between the extent of symptoms (dyspnoea-12 score and fatigue score) and multi-organ injury.

Time: 3,6,12months.

No related HPO nodes (Using clinical trials)